- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05544071
Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD
Safety and Efficacy of rTMS on Individualized dlPFC-NAcc Functional Connectivity in Adolescents With Depression and Anhedonia: a Randomized Clinical Trial
This study evaluates a schedule of precise repetitive transcranial magnetic stimulation for depressive adolescent with anhedonia. In this randomized controlled trial, half of the participants will receive repetitive transcranial magnetic stimulation, and the other will receive sham stimulation.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression among adult. The approved method for treatment is 10Hz stimulation over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been successful for many people with treatment-resistant depression. However, a large percentage of adolescents suffering from major depressive disorder (MDD) do not adequately benefit from currently available treatments. One of the limitations is concerns about the safety and efficacy of antidepressant. Recently, researchers have aggressively pursued better treatment strategy such as rTMS to improve adolescent depression with some preliminary success. This study intends to further explore the safety and efficacy of rTMS in the treatment for adolescent major depressive disorder with anhedonia. This study will also look at the change in neuroimaging biomarkers associated with this treatment.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Shaanxi
-
Xi'an, Shaanxi, Kiina, 710032
- Xijing Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or female, 13 to 18 years of age.
- According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE).
- Meet the threshold on the total HAMD17 score of >/=17 at both screening and baseline visits (Day -7 and Day 0).
- Meet the threshold on the total SHAPS score of >/=20 at both screening and baseline visits (Day -7 and Day 0).
- Not take any antidepressants for two or more weeks before screening.
- In good general health, as ascertained by medical history.
- After fully understanding the treatment of transcranial magnetic stimulation, willing to cooperate with the treatment actively and able to provide informed consent.
Exclusion Criteria:
- Current diagnosis of a Substance Use Disorder, with the exception of nicotine and caffeine dependence.
- Current diagnosis of mental disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is clinically unstable, and/or the focus of the participant's treatment for the past six months or more).
- History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes.
- Any other Mental Disorders, Personality Disorders, Intellectual Disability, which at screening is clinically predominant to their MDD.
- Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results.
- Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
- Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.
- History of electronic instrument or metal in the head or skull.
- History of epilepsy.
- History of cardiovascular disease or cardiac event.
- History of OCD.
- History of autism spectrum disorder.
- History of rTMS exposure.
- Other situations judged by the researchers to be unsuitable for the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: rTMS Active
Blinded Active TMS coil. Active repetitive Transcranial Magnetic Stimulation (rTMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.) |
Compare active coil with sham coil.
Muut nimet:
|
|
Huijausvertailija: rTMS Sham
Blinded Sham TMS coil. Sham Transcranial Magnetic Stimulation (TMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.) |
Compare active coil with sham coil.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percent Change in the Snaith-Hamilton Pleasure Scale (SHAPS)Score From Pre-treatment to 8-weeks
Aikaikkuna: Pre-treatment and 8-weeks post treatment
|
A 14 item self-assessment questionnaire used to measure the severity of anhedonia symptom in patients with mood disorders. Scale range - 14 to 56 with higher score indicative of greater anhedonia symptomology. |
Pre-treatment and 8-weeks post treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Score of the Hamilton Rating Scale for Depression (HAM-17)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
A provider administered questionnaire used to assess remission and recovery from depression. Scale range - 0 to 52 with higher score indicative of greater depressive symptomology. Additional collection time points were prespecified; only those time points for which data were collected are reported. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Montgomery Asberg Depression Rating Scale (MADRS)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
A diagnostic questionnaire used to measure the severity of depressive symptoms. Scale range - 0 to 60 with higher score indicative of greater depressive symptomology. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Chinese version of Temporal Experience of Pleasure Scale(CV-TEPS)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
A 20 item self-assessment questionnaire, eleven items used to measure anticipatory anhedonia, and nine items used to evaluate consummatory anhedonia. Scale range - 0 to 140 with lower score indicative of greater anhedonia symptomology. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Chinese version of Beck Scale for Suicide Ideation(BSI-CV)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
A 19 item questionnaire used to evaluate the severity of suicidal ideation. The scale includes two subscales of suicidal ideation (Current suicidal ideation, BSI-C) and suicidal ideation (Suicidal ideation at one's worst point, BSI-W) in the last week. Scale range - 0 to 38, the higher the score of the subscale, the higher the level of suicidal ideation in the last week or the most serious. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Insomnia Severity Index Scale (ISI)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
The questionnaire consists of seven items: the severity of insomnia symptoms, the satisfaction of sleep patterns, the effects of insomnia on daytime function, the effects of insomnia on subjects' quality of life, and the degree of worry or depression caused by insomnia. Scale range - 0 to 28 with higher score indicative of greater Insomnia symptomology. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Clinical Global Impression (CGI)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
The questionnaire used to evaluate the clinical efficacy, it includes three parts: severity of illness (SI), global improvement (GI) and effect index (EI). With higher score indicative of more serious disease and worse effect. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Score of the Snaith-Hamilton Pleasure Scale (SHAPS)
Aikaikkuna: Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
A 14 item self-assessment questionnaire used to measure the severity of anhedonia symptom in patients with mood disorders. Scale range - 14 to 56 with higher score indicative of greater anhedonia symptomology. |
Baseline; Day 7; Day 15; Day 28 (Week 4 from baseline); Day 56 (Week 8 from baseline)
|
|
Change From Baseline Functional Connectivity to 15-days Post-treatment
Aikaikkuna: Time Frame: Pre-treatment, immediately post-treatment (on day 15)
|
We will assess change in resting state fMRI functional connectivity of the nucleus accumbens to the Dorsolateral Prefrontal Cortex and within the reward-related circuits |
Time Frame: Pre-treatment, immediately post-treatment (on day 15)
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
A digital tool named THINC-it® to help assess cognitive functioning
Aikaikkuna: Time Frame: Pre-treatment to 1 week and 15days, 4 weeks, 6 weeks and 8 weeks post-treatment
|
THINC-it® is a screening tool designed to measure cognition, is based on a combination of specific (traditional) neuropsychological tests assessing cognitive functioning, in conjunction with a patient-reported questionnaire. |
Time Frame: Pre-treatment to 1 week and 15days, 4 weeks, 6 weeks and 8 weeks post-treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Zheng K, Chen L, Wang H; DIRECT consortium; Li B, Chen B. Beyond depression symptoms: the default mode network as a predictor of antidepressant response. Npj Ment Health Res. 2026 Jan 16;5(1):2. doi: 10.1038/s44184-025-00182-2.
- Zheng K, Zheng X, Shi H, Chen L, Li L; DIRECT consortium; Hu D, Friston KJ, Wang H, Li B, Chen B. Brain contrastive modeling reveals depression subtypes with distinct treatment response and progression. NPJ Digit Med. 2026 Jul 20. doi: 10.1038/s41746-026-03011-8. Online ahead of print.
- Lv R, Cai M, Tang N, Shi Y, Zhang Y, Liu N, Han T, Zhang Y, Wang H. Active versus sham DLPFC-NAc rTMS for depressed adolescents with anhedonia using resting-state functional magnetic resonance imaging (fMRI): a study protocol for a randomized placebo-controlled trial. Trials. 2024 Jan 13;25(1):44. doi: 10.1186/s13063-023-07814-y.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- KY20222165-F-1
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .